澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

MESOBLAST LTD

2.190

0.000

成交量：297.17萬

成交額：655.62萬

市值：28.26億

市盈率：-20.51

高：2.260

開：2.220

低：2.180

收：2.190

52周最高：3.310

52周最低：1.515

股本：12.90億

流通股本：7.86億

量比：0.83

換手率：0.38%

股息：- -

股息率：- -

每股收益(TTM):-0.107

每股收益(LYR):-0.123

淨資產收益率：-18.22%

總資產收益率：-6.16%

市淨率：3.39

市盈率(LYR):-17.84

資料載入中...

總覽公司新聞資訊公告

異動解讀 | Mesoblast公布上半年業績虧損4020萬美元，股價盤中大跌7.23%

Mesoblast公布上半年總收入5130萬美元

異動解讀 | Mesoblast核心產品收入預期樂觀，股價盤中大漲5.79%

Mesoblast Limited預計2026財年Ryoncil淨收入將達1.1億至1.2億美元

FDA確認Rexlemestrocel-L在疼痛強度上展現積極效果，12個月背痛減輕數據支持產品療效

獨立研究在美國血液學會年會上提出，Remestemcel-L在治療SR-Agvhd的臨床效果上優於Ruxolitinib

異動解讀 | Mesoblast股價盤中大漲6.72%，預計季度收入超3000萬美元

Mesoblast Limited - 預計2025年12月31日季度毛收入超過3000萬美元，來自Ryoncil的銷售

Mesoblast宣佈James M. O’Brien被任命為首席財務官

新聞稿：詹姆斯·M·奧布萊恩被任命為美莎比信託首席財務官

BUZZ-奧布萊恩出任美國分部財務總監，Mesoblast 的澳大利亞股票攀升

Mesoblast將於下月與FDA會談討論Rexlemestrocel-L和阿片類藥物戒斷

Mesoblast將於下月與FDA會面討論Rexlemestrocel-L和藥物戒斷

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hant/stock/MSB.AU/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MSB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":2.19,"timestamp":1774501920000,"preClose":2.19,"halted":0,"volume":2971710,"delay":0,"changeRate":0,"nameEN":"MESOBLAST LTD","floatShares":786490638,"shares":1290302187,"eps":-0.10679134001108766,"marketStatus":"未開盤","change":0,"latestTime":"03-26 16:12:00 AEDT","open":2.22,"high":2.26,"low":2.18,"amount":6556205,"amplitude":0.03653,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.10679134001108766,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1774566000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":2.19,"openAndCloseTimeList":[[1774479600000,1774501200000]],"volumeRatio":0.8320999020814753,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"MSB.AU","preClose":2.19,"auctionPrice":2.2,"auctionVolume":4000,"auctionTime":1774558112700,"referenceTime":1774517404089,"auction":1,"marketStatus":"盘前竞价","timestamp":1774558112700}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","floatShares":786490638,"roa":"-6.16%","roe":"-18.22%","lyrEps":-0.122732,"volumeRatio":0.8320999020814753,"shares":1290302187,"dividePrice":0,"high":2.26,"amplitude":0.03653,"preClose":2.19,"low":2.18,"week52Low":1.515,"pbRate":"3.39","psRate":"29.78","week52High":3.31,"institutionHeld":0,"latestPrice":2.19,"eps":-0.10679134001108766,"divideRate":0,"volume":2971710,"delay":0,"ttmEps":-0.10679134001108766,"open":2.22,"prevYearClose":2.72,"prevWeekClose":2.06,"prevMonthClose":2.24,"prevQuarterClose":2.72,"fiveDayClose":2.07,"twentyDayClose":2.42,"sixtyDayClose":2.8,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSB.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSB.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1127354637","title":"異動解讀 | Mesoblast公布上半年業績虧損4020萬美元，股價盤中大跌7.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=1127354637","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127354637?lang=zh_tw&edition=fundamental","pubTime":"2026-02-27 10:22","pubTimestamp":1772158948,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd (MSB.AU) 今日盘中股价大跌7.23%，引起了市场的广泛关注。消息面上，公司公布了上半年的财务业绩，虽然总收入达到5130万美元，但归属于公司的亏损高达4020万美元。这一显著的亏损数据可能引发了投资者对公司盈利能力和财务状况的担忧，从而导致股价在交易时段内出现大幅下跌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MSB.AU"],"gpt_icon":0},{"id":"1171017622","title":"Mesoblast公布上半年總收入5130萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1171017622","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171017622?lang=zh_tw&edition=fundamental","pubTime":"2026-02-27 10:15","pubTimestamp":1772158552,"startTime":"0","endTime":"0","summary":"2月27日（路透社）—— Mesoblast Ltd 发布中期业绩公告：*上半年总收入达5130万美元* *归属于公司亏损为4020万美元*\n更多公司相关报道可参考股票代码MSB.AX。\n（信息来源：路透社简报；发布时间：2026年2月27日02:03:10 GMT）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7067","MSB.AU","BK7508"],"gpt_icon":0},{"id":"1164807609","title":"異動解讀 | Mesoblast核心產品收入預期樂觀，股價盤中大漲5.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=1164807609","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164807609?lang=zh_tw&edition=fundamental","pubTime":"2026-02-27 07:03","pubTimestamp":1772146980,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd (MSB.AU) 今日盘中大涨5.79%，引起了市场的广泛关注。消息面上，Mesoblast Limited预计其核心产品Ryoncil在2026财年的全年净收入将介于1.1亿美元至1.2亿美元之间，这一积极的财务预期反映了公司对产品商业化前景的信心，可能提振了投资者情绪。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MSB.AU"],"gpt_icon":0},{"id":"1110626132","title":"Mesoblast Limited預計2026財年Ryoncil淨收入將達1.1億至1.2億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1110626132","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110626132?lang=zh_tw&edition=fundamental","pubTime":"2026-02-27 05:53","pubTimestamp":1772142784,"startTime":"0","endTime":"0","summary":"生物技术企业Mesoblast Limited最新预测显示，其核心产品Ryoncil在2026财年的全年净收入预计将介于1.1亿美元至1.2亿美元之间。这一预期反映了公司对产品商业化前景的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MESO","BK7501","BK7508","MSB.AU","BK7067"],"gpt_icon":0},{"id":"1118834527","title":"FDA確認Rexlemestrocel-L在疼痛強度上展現積極效果，12個月背痛減輕數據支持產品療效","url":"https://stock-news.laohu8.com/highlight/detail?id=1118834527","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118834527?lang=zh_tw&edition=fundamental","pubTime":"2026-01-19 08:02","pubTimestamp":1768780936,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式认可Rexlemestrocel-L在缓解疼痛强度方面表现出显著优势。最新数据显示，该疗法在12个月内持续减轻背痛的效果，进一步验证了其临床有效性。这一进展为MESOBLAST LTD旗下产品的应用前景提供了有力支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7501","BK7508","MSB.AU"],"gpt_icon":0},{"id":"1100916668","title":"獨立研究在美國血液學會年會上提出，Remestemcel-L在治療SR-Agvhd的臨床效果上優於Ruxolitinib","url":"https://stock-news.laohu8.com/highlight/detail?id=1100916668","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100916668?lang=zh_tw&edition=fundamental","pubTime":"2025-12-12 07:26","pubTimestamp":1765495606,"startTime":"0","endTime":"0","summary":"独立研究在美国血液学会年会上提出，Remestemcel-L在治疗SR-Agvhd的临床效果上优于Ruxolitinib","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","MSB.AU","BK7501","BK7508"],"gpt_icon":0},{"id":"1115028816","title":"異動解讀 | Mesoblast股價盤中大漲6.72%，預計季度收入超3000萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1115028816","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115028816?lang=zh_tw&edition=fundamental","pubTime":"2025-11-26 07:03","pubTimestamp":1764111792,"startTime":"0","endTime":"0","summary":"澳大利亚生物技术公司Mesoblast Limited今日盘中股价大涨6.72%，引起投资者广泛关注。此轮涨势主要源于公司发布的积极财务预期。Mesoblast预计截至2025年12月31日的季度毛收入将超过3000万美元，这一收入主要来自其重磅产品Ryoncil的销售。Ryoncil是Mesoblast的主打产品，用于治疗急性移植物抗宿主病。该产品的强劲销售表现不仅直接提升了公司的财务状况，也增强了投资者对Mesoblast长期发展前景的信心。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MSB.AU"],"gpt_icon":0},{"id":"1109683405","title":"Mesoblast Limited - 預計2025年12月31日季度毛收入超過3000萬美元，來自Ryoncil的銷售","url":"https://stock-news.laohu8.com/highlight/detail?id=1109683405","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109683405?lang=zh_tw&edition=fundamental","pubTime":"2025-11-25 22:45","pubTimestamp":1764081909,"startTime":"0","endTime":"0","summary":"Mesoblast Limited - 预计2025年12月31日季度毛收入超过3000万美元，来自Ryoncil的销售","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","BK4139","MESO","BK7501","MSB.AU"],"gpt_icon":0},{"id":"1182398223","title":"Mesoblast宣佈James M. O’Brien被任命為首席財務官","url":"https://stock-news.laohu8.com/highlight/detail?id=1182398223","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182398223?lang=zh_tw&edition=fundamental","pubTime":"2025-11-17 16:14","pubTimestamp":1763367269,"startTime":"0","endTime":"0","summary":"11月17日 - Mesoblast Ltd：James M. O’Brien被任命为Mesoblast的首席财务官。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","BK7067","MSB.AU"],"gpt_icon":0},{"id":"1195991725","title":"新聞稿：詹姆斯·M·奧布萊恩被任命為美莎比信託首席財務官","url":"https://stock-news.laohu8.com/highlight/detail?id=1195991725","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195991725?lang=zh_tw&edition=fundamental","pubTime":"2025-11-17 14:56","pubTimestamp":1763362561,"startTime":"0","endTime":"0","summary":"纽约，2025年11月17日-- 美莎比信托，全球领先的用于治疗炎症性疾病的同种异体细胞药物公司，今天宣布，在公司向一个完全整合的商业组织转型之际，任命詹姆斯·M·奥布莱恩为其美国首席财务官。詹姆斯在财务管理和规划的各个方面拥有丰富经验，职业生涯的大部分时间都在生命科学、生物技术和制药行业的跨国公私公司中度过。本发布已获首席执行官授权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4575","BK7067","MESO","BK4150","R","BK4022","BK4232","BK4139","BK4006","BK7508","BMS","CFO","MSC","BK7501","MSB","MSB.AU"],"gpt_icon":0},{"id":"2584924916","title":"BUZZ-奧布萊恩出任美國分部財務總監，Mesoblast 的澳大利亞股票攀升","url":"https://stock-news.laohu8.com/highlight/detail?id=2584924916","media":"路透中文","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584924916?lang=zh_tw&edition=fundamental","pubTime":"2025-11-17 09:11","pubTimestamp":1763341883,"startTime":"0","endTime":"0","summary":"11月17日 - ** 在澳大利亚证券交易所上市的炎症性疾病药物生产商Mesoblast MSB.AX的股价上涨3.6%，达到2.3澳元，结束了连续两个交易日的下跌。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nL4T3WT01H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","BK7067","BK4007","MSB.AU","CGTX"],"gpt_icon":0},{"id":"1116191251","title":"Mesoblast將於下月與FDA會談討論Rexlemestrocel-L和阿片類藥物戒斷","url":"https://stock-news.laohu8.com/highlight/detail?id=1116191251","media":"投资观察","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116191251?lang=zh_tw&edition=fundamental","pubTime":"2025-11-05 09:45","pubTimestamp":1762307124,"startTime":"0","endTime":"0","summary":"11月5日（路透社） - Mesoblast Ltd：*MESOBLAST将于下月与FDA会面，讨论Rexlemestrocel-L和阿片类药物戒断* 进一步公司报道：MSB.AX","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7501","BK7508","MSB.AU"],"gpt_icon":0},{"id":"1199521939","title":"Mesoblast將於下月與FDA會面討論Rexlemestrocel-L和藥物戒斷","url":"https://stock-news.laohu8.com/highlight/detail?id=1199521939","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199521939?lang=zh_tw&edition=fundamental","pubTime":"2025-11-05 06:59","pubTimestamp":1762297168,"startTime":"0","endTime":"0","summary":"Mesoblast将于下月与FDA会面，讨论Rexlemestrocel-L和药物戒断的相关事宜。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MESO","BK7508","BK7501","BK7067","MSB.AU","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":13,"code":"91000000","status":"200"}]}}